Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2B | Q13224 | 12/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 8/20 | 0.55 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3489982 | 0.79 | SLC2A1 (0.54) | MAPTTP53NR3C2 | |
| SCHEMBL3488053 | 0.77 | NR3C2 (0.52) | GRIN2BGRIN1RIPK3TP53ALDH1A1 | |
| SCHEMBL3489611 | 0.76 | MAPT (0.52) | MAPTALDH1A1NR3C2NPC1L3MBTL1 | |
| SCHEMBL3489954 | 0.76 | MAPT (0.39) | GRIN2BGRIN1MAPTALDH1A1NR3C2 | |
| SCHEMBL3488088 | 0.76 | SLC2A1 (0.50) | RIPK3MAPTTP53ALDH1A1NR3C2 | |
| SCHEMBL3488270 | 0.76 | PGR (0.49) | MAPTALDH1A1NR3C2 | |
| SCHEMBL3488787 | 0.74 | NR3C2 (0.50) | RIPK3MAPTNR3C2 | |
| SCHEMBL3488094 | 0.74 | SLC2A1 (0.40) | MAPTTP53ALDH1A1NR3C2 | |
| SCHEMBL3488122 | 0.74 | MAPT (0.39) | MAPTALDH1A1NR3C2 | |
| SCHEMBL3488754 | 0.74 | L3MBTL1 (0.47) | MAPTTP53ALDH1A1NR3C2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100094000-A1 | PYRAZOLE COMPOUNDS | NR3C2, MC2R, NR3C1 | GRIN2B 965/4885GRIN1 778/4885RIPK3 2132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.